JP7410720B2 - 皮膚疾患を治療するための局所組成物および方法 - Google Patents

皮膚疾患を治療するための局所組成物および方法 Download PDF

Info

Publication number
JP7410720B2
JP7410720B2 JP2019562657A JP2019562657A JP7410720B2 JP 7410720 B2 JP7410720 B2 JP 7410720B2 JP 2019562657 A JP2019562657 A JP 2019562657A JP 2019562657 A JP2019562657 A JP 2019562657A JP 7410720 B2 JP7410720 B2 JP 7410720B2
Authority
JP
Japan
Prior art keywords
topical pharmaceutical
pharmaceutical composition
tazarotene
oil
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019562657A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020519656A (ja
JP2020519656A5 (enExample
Inventor
アンヘル，アルトゥーロ
ピライ，ラーダークリシュナン
Original Assignee
ボシュ ヘルス アイルランド リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ボシュ ヘルス アイルランド リミテッド filed Critical ボシュ ヘルス アイルランド リミテッド
Publication of JP2020519656A publication Critical patent/JP2020519656A/ja
Publication of JP2020519656A5 publication Critical patent/JP2020519656A5/ja
Application granted granted Critical
Publication of JP7410720B2 publication Critical patent/JP7410720B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cosmetics (AREA)
JP2019562657A 2017-05-12 2018-05-11 皮膚疾患を治療するための局所組成物および方法 Active JP7410720B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762505421P 2017-05-12 2017-05-12
US62/505,421 2017-05-12
PCT/US2018/032359 WO2018209262A1 (en) 2017-05-12 2018-05-11 Topical compositions and methods for treating skin diseases

Publications (3)

Publication Number Publication Date
JP2020519656A JP2020519656A (ja) 2020-07-02
JP2020519656A5 JP2020519656A5 (enExample) 2021-07-26
JP7410720B2 true JP7410720B2 (ja) 2024-01-10

Family

ID=62386996

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019562657A Active JP7410720B2 (ja) 2017-05-12 2018-05-11 皮膚疾患を治療するための局所組成物および方法

Country Status (8)

Country Link
US (1) US20180360752A1 (enExample)
EP (1) EP3621614B1 (enExample)
JP (1) JP7410720B2 (enExample)
BR (1) BR112019023817A8 (enExample)
CA (1) CA3063371A1 (enExample)
PL (1) PL3621614T3 (enExample)
RS (1) RS67211B1 (enExample)
WO (1) WO2018209262A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108282998B (zh) 2015-06-18 2021-07-06 凡利亚药品北美公司 用于治疗银屑病的包含皮质类固醇和类视黄醇的局部组合物
US11311482B2 (en) 2017-05-12 2022-04-26 Bausch Health Us, Llc Topical compositions and methods for treating skin diseases
CA3267519A1 (en) * 2022-09-16 2024-03-21 Bausch Health Ireland Ltd METHODS FOR TREATING ACNE AND OILY SKIN WITH TAZAROTENE

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1528328A (zh) 2003-09-29 2004-09-15 中国医学科学院皮肤病研究所 治疗痤疮的复方外用药物
WO2016205001A1 (en) 2015-06-18 2016-12-22 Valeant Pharmaceuticals North America Topical compositions comprising a corticosteroid and a retinoid for treating psoriasis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1528328A (zh) 2003-09-29 2004-09-15 中国医学科学院皮肤病研究所 治疗痤疮的复方外用药物
WO2016205001A1 (en) 2015-06-18 2016-12-22 Valeant Pharmaceuticals North America Topical compositions comprising a corticosteroid and a retinoid for treating psoriasis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Cutis，1999年，Vol.63，pp.349-354
J. Drug Dermatol.，2009年，Vol.8 Iss.7，pp.650-654

Also Published As

Publication number Publication date
PL3621614T3 (pl) 2025-10-13
BR112019023817A8 (pt) 2022-12-06
JP2020519656A (ja) 2020-07-02
BR112019023817A2 (pt) 2020-06-02
CA3063371A1 (en) 2018-11-15
RS67211B1 (sr) 2025-10-31
EP3621614A1 (en) 2020-03-18
US20180360752A1 (en) 2018-12-20
WO2018209262A1 (en) 2018-11-15
EP3621614B1 (en) 2025-06-25

Similar Documents

Publication Publication Date Title
US11648256B2 (en) Topical compositions and methods for treating psoriasis
US20250017854A1 (en) Topical compositions and methods for treating skin diseases
JP7410720B2 (ja) 皮膚疾患を治療するための局所組成物および方法
US20190133943A1 (en) Topical compositions and methods for treating skin diseases
WO2003049716A1 (en) Stable topical formulation of clarithromycin
EP1675621B1 (en) Pharmaceutical compositions of lavendustin
US20050037030A1 (en) Stable topical formulation of clarithromycin
HK1092699B (en) Pharmaceutical compositions of lavendustin

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210511

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210511

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220323

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220620

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20220707

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220926

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230104

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230404

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230704

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231115

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231206

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231222

R150 Certificate of patent or registration of utility model

Ref document number: 7410720

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150